Related Experiment Video
Updated: Aug 24, 2025

In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding
Published on: May 1, 2020
HDAC5-mediated Smad7 silencing through MEF2A is critical for fibroblast activation and hypertrophic scar formation
Ya Gao1, Yangdan Liu1, Danning Zheng1
1Department of Plastic & Reconstructive Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Abstract:
Transforming growth factor-β (TGF-β) signaling plays a key role in excessive fibrosis. As a class IIa family histone deacetylase (HDAC), HDAC5 shows a close relationship with TGF-β signaling and fibrosis. However, the effect and regulatory mechanism of HDAC5 in hypertrophic scar (HS) formation remain elusive. We show that HDAC5 was overexpressed in HS tissues and depletion of HDAC5 attenuated HS formation in vivo and inhibited fibroblast activation in vitro. HDAC5 knockdown (KD) significantly downregulated TGF-β1 induced Smad2/3 phosphorylation and increased Smad7 expression. Meanwhile, Smad7 KD rescued the Smad2/3 phosphorylation downregulation and scar hyperplasia inhibition mediated by HDAC5 deficiency. Luciferase reporter assays and ChIP-qPCR assays revealed that HDAC5 interacts with myocyte enhancer factor 2A (MEF2A) suppressing MEF2A binding to the Smad7 promoter region, which results in Smad7 promoter activity repression. HDAC4/5 inhibitor, LMK235, significantly alleviated hypertrophic scar formation. Our study provides clues for the development of HDAC5 targeting strategies for the therapy or prophylaxis of fibrotic diseases.
Insights
Histone deacetylase 5 (HDAC5) promotes hypertrophic scar formation by inhibiting Smad7. Inhibiting HDAC5 reduces scarring, offering a potential therapeutic strategy for fibrotic diseases.
Area of Science:
- Biochemistry
- Molecular Biology
- Dermatology
Background:
- Transforming growth factor-β (TGF-β) signaling is crucial in fibrosis.
- Histone deacetylase 5 (HDAC5) is linked to TGF-β signaling and fibrosis, but its role in hypertrophic scarring is unclear.
Purpose of the Study:
- To investigate the role and regulatory mechanism of HDAC5 in hypertrophic scar (HS) formation.
- To explore HDAC5 as a potential therapeutic target for fibrotic diseases.
Main Methods:
- Assessed HDAC5 expression in HS tissues and its effect on fibroblast activation.
- Utilized knockdown and inhibitor studies to analyze the TGF-β/Smad signaling pathway.
- Employed luciferase reporter and ChIP-qPCR assays to determine the interaction between HDAC5, MEF2A, and the Smad7 promoter.
Main Results:
- HDAC5 was overexpressed in HS tissues and its depletion attenuated scar formation and fibroblast activation.
- HDAC5 knockdown downregulated TGF-β1-induced Smad2/3 phosphorylation and increased Smad7 expression.
- HDAC5 suppresses Smad7 expression by inhibiting MEF2A binding to the Smad7 promoter, and LMK235 alleviated HS formation.
Conclusions:
- HDAC5 plays a significant role in hypertrophic scar formation.
- Targeting HDAC5 presents a promising therapeutic strategy for managing fibrotic diseases like hypertrophic scarring.
More Related Videos
Related Concept Videos
TGF - β Signaling Pathway
Master Transcription Regulators
Hedgehog Signaling Pathway
MAPK Signaling Cascades

